Sanofi has decided to discontinue the clinical development of amlitelimab, a monoclonal antibody intended for moderate-to-severe atopic dermatitis (AD). This decision follows a review of efficacy and safety data, which concluded that the drug does not offer a significant improvement over current treatment options. The company will now wind down ongoing studies and ensure a smooth transition of care for patients involved.
Despite Sanofi's previous intentions to seek regulatory approval for amlitelimab globally, partly to secure a successor to its best-selling drug Dupixent, the recent assessment has led to the halt in development. Mixed study results had previously been reported, with amlitelimab meeting primary endpoints in some U.S.-focused analyses but missing statistical thresholds for European regulators due to differences in how non-responders were classified.
Concerns over amlitelimab's market potential intensified after a case of Kaposi's sarcoma, a type of skin cancer, was observed in a treatment recipient during a safety study. Analysts speculated that this could lead to a "black box" safety warning from the FDA, further complicated by the drug's perceived weaker efficacy compared to Dupixent in cross-trial comparisons. Shares in Sanofi had previously dropped by more than 10%, wiping out nearly $13 billion from its market value, due to disappointing trial data and concerns about its competitive positioning against Dupixent, which is set to lose patent protection in 2031.
While Sanofi will present further study results at a future medical meeting, the immediate impact is the cessation of amlitelimab's development. This move highlights the company's strategic decision to prioritize treatments that offer clear advantages in the competitive landscape of inflammatory skin conditions.
